Day: February 27, 2025

Record fourth quarter home sales revenue of $450.6 million Record fourth quarter home closings of 937, up 41% Record full year total revenue of $1.55 billion Fourth quarter net new home orders of 636, up 60% Fourth quarter cash from operations of $47.8 million Fourth quarter net income of $3.0 million, or $0.08 per diluted share Full year net income of $17.2 million or $0.47 per diluted share Year-end book value per share of $18.37DALLAS, Feb. 27, 2025 (GLOBE NEWSWIRE) — Landsea Homes Corporation (Nasdaq: LSEA) (“Landsea Homes” or the “Company”) announced today financial results for the fourth quarter and full year ended December 31, 2024. For the quarter, the Company reported pretax income of $6.5 million and net income of $3.0 million, or $0.08 per diluted share. Adjusted net income (a non-GAAP measure) was $9.1 million or...

Solid Finish to 2024; Record Full Year Revenue and Gross Margins SANTA ANA, Calif., Feb. 27, 2025 (GLOBE NEWSWIRE) — Ducommun Incorporated (NYSE: DCO) (“Ducommun” or the “Company”) today reported results for its fourth quarter and year ended December 31, 2024. Fourth Quarter 2024 RecapNet revenue of $197.3 million, an increase of 2.6% over Q4 2023 Gross margin of 23.5% showed year-over-year growth of 180 bps Net income of $6.8 million increased 33% year-over-year, or $0.45 per diluted share, or 3.4% of revenue, up 70 bps year-over-year Non-GAAP adjusted net income for the quarter of $11.4 million which increased 9% year-over-year, or $0.75 per diluted share Adjusted EBITDA of $27.3 million (increase of 19% year-over-year), or 13.8% of revenue, up 180 bps year-over-year“We made excellent progress in our VISION 2027 commitments...

OhtuvayreTM (ensifentrine) recorded net product sales of $36.6 million in Q4 and $42.3 million in 2024 More prescriptions filled through February 2025 than in Q4 2024 Over 4,600 unique prescribers with ~55% of Tier 1 HCPs prescribing Ohtuvayre through February 2025 Phase 2 programs in bronchiectasis and fixed-dose combination in COPD advance Conference call today at 9:00 a.m. EST / 2:00 p.m. GMT LONDON and RALEIGH, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) — Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a biopharmaceutical company focused on respiratory diseases, announces its financial results for the fourth quarter and full year ended December 31, 2024, and provides a corporate update. “2024 was another transformational year for Verona Pharma with the US approval and launch of Ohtuvayre (ensifentrine), the first...

FY24 net sales of $3,793 million decreased (4.3%), organic sales decreased (3.5%) including a (1.2%) Byte sales impact FY24 GAAP net loss of ($910) million or ($4.48) per share, adjusted EPS of $1.67 Q4 net sales of $905 million decreased (10.6%), organic sales decreased (10.7%) including a (6.0%) Byte sales impact Q4 GAAP net loss of ($430) million or ($2.16) per share, adjusted EPS of $0.26 FY25 outlook: net sales in the range of $3.50 billion to $3.60 billion with organic sales down (4.0%) to (2.0%); adjusted EPS of $1.80 to $2.00(1)CHARLOTTE, N.C., Feb. 27, 2025 (GLOBE NEWSWIRE) — DENTSPLY SIRONA Inc. (“Dentsply Sirona” or the “Company”) (Nasdaq: XRAY) today announced its financial results for the fourth quarter and full year of 2024. Full year 2024 net sales of $3,793 million decreased (4.3%) (organic sales decreased (3.5%)...

All 2024 Operating and Financial Metrics Above High End of Guidance Ranges Very strong New Provider Signings with Implemented Providers +11.2% from Year-end 2023 Full-year 2024 Net Cash Provided by Operating Activities of $109.3 million, +35.3% from 2023, with De Minimis Capital Expenditures Year-end 2024 Cash Balance of $491.1 million and No Debt 2025 Guidance Reflects Continued Momentum and Profitable Growth Despite Challenging Medicare Advantage and Value-based EnvironmentARLINGTON, Va., Feb. 27, 2025 (GLOBE NEWSWIRE) — Privia Health Group, Inc. (Nasdaq: PRVA) today announced financial and operating results for the fourth quarter and full year ended December 31, 2024. Each of the Company’s operating and financial performance metrics were above the high end of its guidance ranges for 2024, as highlighted below. Full-Year Performance    For...

Fourth quarter 2024 net sales of $2.8 billion and earnings per diluted share of $2.09, both exceeding guidance Fourth quarter net sales performance driven by strong traffic and conversion, building on Q3 momentum Company provides 2025 annual guidance of 1% to 3% net sales growth and earnings per diluted share of $3.25 to $3.60 Board of Directors authorizes new $500M share repurchase programCOLUMBUS, Ohio, Feb. 27, 2025 (GLOBE NEWSWIRE) — Bath & Body Works, Inc. (NYSE: BBWI), a global leader in personal care and home fragrance, today reported fourth quarter and full-year fiscal 2024 results. Gina Boswell, CEO of Bath & Body Works, commented, “Our team delivered strong performance that exceeded expectations on both the top and bottom line in the critical fourth quarter. This success was driven by our product innovation,...

Leading Macau’s Non-Gaming Diversification Through Mice, Entertainment Events And Live Sports Capella At Galaxy Macau Fitting Out – Mid Year Opening Q4 2024 Group Adjusted EBITDA Up 15% YoY And Up 10% QoQ To $3.2 Billion FY2024 Group Adjusted EBITDA Up 22% YoY To $12.2 Billion FY2024 Group NPAS Up 28% YoY to $8.8 Billion Recommends A Final Dividend Of $0.50 Per Share HONG KONG, Feb. 27, 2025 (GLOBE NEWSWIRE) — Galaxy Entertainment Group (“GEG”, “Company” or the “Group”) (HKEx stock code: 27) today reported results for the three-month and twelve-month periods ended 31 December 2024. (All amounts are expressed in HKD unless otherwise stated) Mr. Francis Lui, Chairman of GEG said, “Before I update you on GEG’s performance in 2024, I would like firstly to acknowledge the passing of Dr. Lui Che Woo in November 2024. As the founding...